Your browser doesn't support javascript.
loading
Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years.
Park, Yewan; Na, Seong-Kyun; Yoon, Jae-Hyun; Kim, Sung-Eun; Park, Ji-Won; Kim, Gi-Ae; Lee, Hyo-Young; Lee, Young-Sun; Kim, Jeong-Han.
Afiliación
  • Park Y; Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea.
  • Na SK; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Republic of Korea.
  • Yoon JH; Department of Internal Medicine, School of Medicine, Chonnam National University Hospital, Gwangju 61469, Republic of Korea.
  • Kim SE; Department of Internal Medicine, Hallym University College of Medicine, Anyang 14068, Republic of Korea.
  • Park JW; Department of Internal Medicine, Hallym University College of Medicine, Anyang 14068, Republic of Korea.
  • Kim GA; Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea.
  • Lee HY; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Republic of Korea.
  • Lee YS; Department of Internal Medicine, Korea University Medical Center, Seoul 08308, Republic of Korea.
  • Kim JH; Department of Internal Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.
Medicina (Kaunas) ; 60(7)2024 Jul 14.
Article en En | MEDLINE | ID: mdl-39064561
ABSTRACT
Background and

Objectives:

Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016. Patients who achieve a sustained virologic response (SVR) following DAA treatment are predicted to have a favorable prognosis. Nevertheless, little is known regarding the prognosis of Korean CHC patients who receive SOF-based treatment and achieve SVR. Therefore, the purpose of this study was to look into the long-term outcomes for these patients. Materials and

Methods:

This was a prospective, multicenter observational study. CHC patients were enrolled who, following SOF or LDV/SOF treatment, had achieved SVR. The last day for follow-up was December 2023. The primary endpoint was HCC occurrence, which was checked at least once per year.

Results:

A total of 516 patients were included in this analysis, with a median follow-up duration of 39.0 months. Among them, 231 were male patients (44.8%), with a median age of 62.0 years. Genotypes were 1 (90, 17.4%), 2 (423, 82.0%), and 3 (3, 0.6%). The combination of SOF plus ribavirin was the most common treatment (394, 76.4%). In total, 160 patients were cirrhotic (31.0%), and the mean Child-Pugh score was 5.1. Within a maximum of 7 years, 21 patients (4.1%) developed HCC. Patients with HCC were older (69 vs. 61 years, p = 0.013) and had a higher cirrhosis incidence (81.0 vs. 28.9%, p < 0.001), higher AFP (6.0 vs. 3.3, p = 0.003) and higher APRI (0.8 vs. 0.5, p = 0.005). Age over 65 (p = 0.016) and cirrhosis (p = 0.005) were found to be significant risk factors for HCC by Cox regression analysis.

Conclusions:

Patients who achieved SVR with SOF-based treatment had a relatively favorable prognosis. However, the risk of HCC was not eliminated, especially in older and cirrhotic patients. Therefore, routine follow-up, surveillance, and early treatment are required.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica / Sofosbuvir / Respuesta Virológica Sostenida Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica / Sofosbuvir / Respuesta Virológica Sostenida Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2024 Tipo del documento: Article Pais de publicación: Suiza